Streetbeat News

Stock Prices

ESALF

ESALY

MRK

Merck & Co Inc (MRK) and Eisai Co Ltd (ESALY, ESALF) announced the Phase 3 LEAP-001 trial of Keytruda plus Lenvima did not meet primary endpoints for treating advanced or recurrent endometrial carcinoma. This follows previous trial failures in lung cancer and melanoma. However, a trial in renal cell carcinoma showed a benefit. MRK shares saw a slight premarket increase.

Portfolio Pulse from Vandana Singh

December 08, 2023 | 1:26 pm

RH

Morgan Stanley analyst Simeon Gutman has maintained an Equal-Weight rating on RH (NYSE:RH) but reduced the price target from $340 to $290.

Portfolio Pulse from Benzinga Newsdesk

December 08, 2023 | 1:25 pm

LULU

Morgan Stanley analyst Alexandra Steiger has maintained an Overweight rating on Lululemon Athletica (NASDAQ:LULU) and increased the price target from $437 to $493.

Portfolio Pulse from Benzinga Newsdesk

December 08, 2023 | 1:23 pm

ENPH

Morgan Stanley analyst Andrew Percoco has maintained an Equal-Weight rating on Enphase Energy (NASDAQ:ENPH) and increased the price target from $94 to $97.

Portfolio Pulse from Benzinga Newsdesk

December 08, 2023 | 1:14 pm

DPZ

Morgan Stanley analyst Brian Harbour has maintained an Overweight rating on Domino's Pizza (NYSE:DPZ) and increased the price target from $435 to $455.

Portfolio Pulse from Benzinga Newsdesk

December 08, 2023 | 1:13 pm

POST

Post Holdings Inc (NYSE:POST) reported avian influenza outbreaks at two contracted egg farms in Iowa and Ohio, affecting 4.2 million hens, about 10% of its supply. Despite this, Post raised its FY24 adjusted EBITDA guidance to $1.22-$1.28 billion, factoring in 10 months of contributions from the acquisition of Perfection Pet Foods, completed on December 1, 2023. The guidance does not account for a significant expansion of avian influenza. POST shares closed up 0.73% at $88.06.

Portfolio Pulse from Lekha Gupta

December 08, 2023 | 1:12 pm

DG

Morgan Stanley analyst Simeon Gutman has maintained an Equal-Weight rating on Dollar General (NYSE:DG) and increased the price target from $125 to $130.

Portfolio Pulse from Benzinga Newsdesk

December 08, 2023 | 1:12 pm

DOCU

Morgan Stanley analyst Josh Baer has maintained an Underweight rating on DocuSign (NASDAQ:DOCU) and reduced the price target from $51 to $49.

Portfolio Pulse from Benzinga Newsdesk

December 08, 2023 | 1:10 pm

DLR

Morgan Stanley analyst Simon Flannery has maintained an Equal-Weight rating on Digital Realty Trust (NYSE:DLR) and increased the price target from $98 to $100.

Portfolio Pulse from Benzinga Newsdesk

December 08, 2023 | 1:09 pm

SGHT

Sight Sciences has announced that the GEMINI 2 trial results, showcasing long-term clinical outcomes for patients treated with the OMNI Surgical System, have been accepted for publication in Clinical Ophthalmology. The publication is anticipated by December 31, 2023.

Portfolio Pulse from Benzinga Newsdesk

December 08, 2023 | 1:09 pm